Literature DB >> 31912271

[IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].

J Stasch-Bouws1, S M Eller-Woywod2, S Schmickler3, J Inderfurth4, P Hoffmann5, C Ohlmeyer6, B Kammering7, D Pauleikhoff8,9,10.   

Abstract

BACKGROUND: The KVWL-QS assists ophthalmologists in the transfer for good clinical praxis into real life. In addition the QS-commission initiated a pilotstudy "Qualitäts-Versorgung bei AMD" (Q‑VERA) in order to test new instruments for improvements. It was analized, if Reading Center (RC) based controls in combination with specific case-management modules can improve the results of IVOM treatment. PATIENTS AND METHODS: In 5 treatment centers 878 consecutive patients with newly diagnosed AMD (Neu-Patienten) were included, who were treated with the IVAN-scheme. Initial FA and OCT images were transferred electronically to the RC. Also 781 retreatment patients (mean 20.7 IVOM before) with retreatment due to lesion activity were observed.
RESULTS: In 5% of the 878 newly treated patients a discrepancy between RC and treatment center was recorded. In this group the 481 patients, who finished up to the analysis date the 12-month follow-up, the visual function (increase in BCVA) and SD-OCT (reduction in central retinal thickness) results were comparable with large prospective cohorts. This was achieved with 6.5 injections and 10.6 visits over 12 months. In the group of 781 patients with repeated injections the number of injections over 12 months was 7.7 and the number of visits 11.6.
CONCLUSION: Quality assessment can improve the efficacy of IVOM therapy for AMD patients in real life. In addition to existing structures, electronical exchange by a RC assisted evaluation can further improve the quality by reducing the number of unnecessary treatment visits. The case-management with adherence control, re-call-system and specific information for patients and relatives can specifically increase the long-term adherence and thus the success of the therapy.

Entities:  

Keywords:  Age-related macular degeneration; Case management; Compliance; Electronic quality assurance; Treatment quality

Mesh:

Substances:

Year:  2020        PMID: 31912271     DOI: 10.1007/s00347-019-01030-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  21 in total

1.  [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].

Authors:  F Ziemssen; N Eter; S Fauser; S Bopp; M Radermacher; Z Hasanbasic; F G Holz
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

2.  [Compliance of age related macular degeneration patients undergoing anti-VEGF therapy : Analysis and suggestions for improvement].

Authors:  B Heimes; F Gunnemann; M Ziegler; M Gutfleisch; G Spital; D Pauleikhoff; A Lommatzsch
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

3.  [Pro re nata anti-VEGF treatment results for neovascular age-related macular degeneration in routine clinical treatment: comparison of single with triple injections].

Authors:  M W M Wintergerst; P P Larsen; B Heimes; D Pauleikhoff; F G Holz; R P Finger
Journal:  Ophthalmologe       Date:  2019-05       Impact factor: 1.059

4.  Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.

Authors:  Robert P Finger; Peter Wiedemann; Francisca Blumhagen; Karin Pohl; Frank G Holz
Journal:  Acta Ophthalmol       Date:  2012-11-22       Impact factor: 3.761

5.  Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying; Glenn J Jaffe; Ebenezer Daniel; Juan E Grunwald; Cynthia A Toth; Frederick L Ferris; Stuart L Fine
Journal:  Ophthalmology       Date:  2016-05-02       Impact factor: 12.079

6.  [Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].

Authors:  B Heimes; T Schick; C K Brinkmann; A Wiedon; B Haegele; B Kirchhof; F G Holz; D Pauleikhoff; F Ziemssen; S Liakopoulos; G Spital; S Schmitz-Valckenberg
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

7.  Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.

Authors:  E Boulanger-Scemama; G Querques; F About; N Puche; M Srour; V Mane; N Massamba; F Canoui-Poitrine; E H Souied
Journal:  J Fr Ophtalmol       Date:  2015-04-23       Impact factor: 0.818

8.  [Health services for patients with neovascular age-related macular degeneration in Germany].

Authors:  R P Finger; F G Holz
Journal:  Ophthalmologe       Date:  2014-05       Impact factor: 1.059

9.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.

Authors:  Frank G Holz; Ramin Tadayoni; Stephen Beatty; Alan Berger; Matteo G Cereda; Rafael Cortez; Carel B Hoyng; Philip Hykin; Giovanni Staurenghi; Stephanie Heldner; Timon Bogumil; Theresa Heah; Sobha Sivaprasad
Journal:  Br J Ophthalmol       Date:  2014-09-05       Impact factor: 4.638

10.  Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.

Authors:  Thomas Wecker; Christoph Ehlken; Anima Bühler; Clemens Lange; Hansjürgen Agostini; Daniel Böhringer; Andreas Stahl
Journal:  Br J Ophthalmol       Date:  2016-05-23       Impact factor: 4.638

View more
  4 in total

Review 1.  Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : Status February 2020.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

Review 2.  [Value and formats of quality assurance : Ophthalmology and intravitreal therapy between reality and wishful thinking].

Authors:  Nicole Eter; Daniel Pauleikhoff; Hansjürgen Agostini; Monika Fleckenstein; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

Review 3.  [Legal aspects of quality assurance : Example of operative intravitreal injection therapy].

Authors:  Reinhold Preißler; Eva Hansmann; Klaus-Dieter Schnarr; Bernd Bertram; Focke Ziemssen
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

4.  Clinically applicable deep learning-based decision aids for treatment of neovascular AMD.

Authors:  Matthias Gutfleisch; Oliver Ester; Sökmen Aydin; Martin Quassowski; Georg Spital; Albrecht Lommatzsch; Kai Rothaus; Adam Michael Dubis; Daniel Pauleikhoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-22       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.